Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 8
Submit an article Journal homepage
273
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices

Alan P. SkarbnikLymphoma Division, Blood and Marrow Transplantation Program, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; Correspondence[email protected]
,
Esprit MaMillennium Pharmaceuticals Inc, Cambridge, MA, USA;
,
Marie-Hélène LafeuilleGroupe d’analyse, Ltée, Montreal, QC, Canada;
,
Jonathan FortierGroupe d’analyse, Ltée, Montreal, QC, Canada;
,
Tatyana FeldmanLymphoma Division, Blood and Marrow Transplantation Program, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA;
,
Mei Sheng DuhAnalysis Group, Inc, Boston, MA, USA
,
Helgi van de VeldeMillennium Pharmaceuticals Inc, Cambridge, MA, USA;
,
Liviu NiculescuMillennium Pharmaceuticals Inc, Cambridge, MA, USA;
,
Vijayveer BonthapallyMillennium Pharmaceuticals Inc, Cambridge, MA, USA;
&
André GoyLymphoma Division, Blood and Marrow Transplantation Program, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA;
show all
Pages 1968-1972 | Received 19 Apr 2016, Accepted 11 Dec 2016, Published online: 16 Jan 2017

References

  • Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin’s lymphomas, version 4.2014. J Natl Compr Canc Netw. 2014;12:1282–1303.
  • Vose JM. Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2013;88:1082–1088.
  • Hitz F, Bargetzi M, Cogliatti S, et al. Diagnosis and treatment of mantle cell lymphoma. Swiss Med Wkly. 2013;143:w13868.
  • Rajguru S, Kahl BS. Emerging therapy for the treatment of mantle cell lymphoma. J Natl Compr Canc Netw. 2014;12:1311–1318.
  • Williams ME. Transplantation for mantle cell lymphoma: is it the right thing to do? Hematology Am Soc Hematol Educ Program. 2013;2013:568–574.
  • Skarbnik AP, Goy AH. Mantle cell lymphoma: state of the art. Clin Adv Hematol Oncol. 2015;13:44–55.
  • Kane RC, Dagher R, Farrell A, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13:5291–5294.
  • Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–4874.
  • Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520–525.
  • Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–953.
  • EMA. Velcade 3.5 mg powder for solution for injection: summary of product characteristics [Internet]; [cited 2015 Mar 19]. Available from: http://www.medicines.org.uk/emc/medicine/17109.
  • Millennium Pharmaceuticals Inc. VELCADE® (bortezomib) for injection: for subcutaneous or intravenous use. Full prescribing information. October 2012, Revision 15 [Internet]; [cited 2014 Mar 19]. Available from: http://www.velcade.com/files/pdfs/velcade_prescribing_information.pdf.
  • Kane RC, Bross PF, Farrell AT, et al. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8:508–513.
  • Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97:1925–1928.
  • Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–440.
  • Lamm W, Drach-Schauer B, Eder S, et al. Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. Oncology. 2013;85:223–227.
  • Larocca A, Cavallo F, Magarotto V, et al. Reduced dose-intensity subcutaneous bortezomib plus prednisone (VP) or plus cyclophosfamide (VCP) or plus melphalan (VMP) for newly diagnosed multiple myeloma patients older than 75 years of age [abstract]. Blood. 2013;122:539.
  • Sidana S, Faiman B, Elson P, et al. Neuropathy and efficacy of weekly subcutaneous bortezomib in myeloma and AL amyloidosis [abstract]. Blood. 2013;122:1975.
  • Simpson D, McCulloch R, Liang J, et al. Weekly subcutaneous bortezomib is well tolerated and effective as initial therapy of symptomatic myeloma [abstract]. Blood. 2013;122:3229.
  • Takamatsu Y, Imamura Y, Nakazato T, et al. Once-weekly subcutaneous bortezomib plus oral cyclophosphamide and dexamethasone therapy for relapsed or refractory multiple myeloma [abstract]. Blood. 2013;122:5382.
  • Takezako N, Sekiguchi N, Nagata A, et al. Subcutaneous injection of bortezomib, combined with doxorubicin and dexamethasone (sPAD) is effective and safety induction therapy for untreated multiple myeloma patients [abstract]. Blood. 2013;122:5391.
  • Gressin R, Callanan M, Daguindau N, et al. Frontline therapy with the Ribvd regimen elicits high clinical and molecular response rates and long PFS in elderly patients mantle cell lymphoma (MCL); final results of a prospective phase II trial by the Lysa group [abstract]. Blood. 2014;124:148.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.